Gilead Sciences, Inc (GIS) Stock Price & News

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia

About Gilead Sciences, Inc

CEODaniel O'Day

Employees17K

FoundedJun 22, 1987

HeadquartersFoster City, California, United States

SectorHealth Care

IndustryBiotechnology

Websitegilead.com

All values in USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	7.92B	6.96B	7.80B	8.30B
Cost of goods sold	1.62B	1.44B	1.58B	1.57B
Cost of revenue	1.62B	1.44B	1.58B	1.57B
Research and development expenses	1.57B	1.36B	1.69B	1.60B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.78B	1.43B	1.91B	1.61B
Operating expense	3.34B	2.78B	3.60B	3.21B
Total operating expenses	4.96B	4.23B	5.18B	4.78B
Operating income	2.96B	2.73B	2.63B	3.52B
Other non operating income	3.00M	-8.00M	-	-7.00M
EBT including unusual items	2.08B	2.58B	-10.25B	3.06B
EBT excluding unusual items	2.80B	2.59B	2.42B	3.29B
Income tax expense	-105.00M	559.00M	242.00M	634.00M
Effective tax rate	-5.05%	21.67%	-2.36%	20.70%
Other operating expenses	-	-	-	-
Net income	2.18B	2.02B	-10.50B	2.43B
Net profit margin	27.55%	29.04%	-134.51%	29.27%
Earnings per share	1.86	2.03	-6.75	2.55
Interest and investment income	95.00M	95.00M	45.00M	41.00M
Interest expense	-255.00M	-240.00M	-247.00M	-269.00M
Net interest expenses	-160.00M	-145.00M	-202.00M	-228.00M
Depreciation and amortization charges	-	-	-	-
EBITDA	3.65B	3.42B	3.33B	4.26B
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything